Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Expert Opinion / Cases · March 16, 2021

Residual ER+ Ductal Carcinoma in Sternum

Written by
Ana C. Sandoval Leon MD


Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Bogdan Cristian Dinu

    Mar 17, 2021

    curative intent. seem to be more accurate.

  • Comment deleted by Moderator.
  • Feng-Jen Chen

    Mar 19, 2021

    Endocrine therapy with ovarian suppression/AI/CDK4/6 inhibitor

  • Rafaat Bakheet

    Mar 19, 2021

    endocrine therapy with ovarian suppression / AI/ CDK4/6  inhibitor

  • Mahmoud  Soliman

    Mar 19, 2021

    Curative intent 

  • Kimberly Langdon

    Mar 19, 2021

    Endocrine therapy with Ovarian suppression/AI treatment Metastatic disease is generally not curable 

  • Eduardo Medeiros

    Mar 20, 2021

    Treat with curative intent as described with SBRT in metastatic areas and long term ádjuvant"endocrine therapy with AI/CDK4/6 inhibitor. Despite incurable disease this approach will probably bring the best long term survival...

  • robert kwiatkowski

    Mar 21, 2021

    Curative intent with SBRT

  • Lee Schwartzberg

    Apr 04, 2021

    Would treat the oligometastatic disease with SBRT and then begin AI/CDK 4/6 inhibitor. If still in remission at 2 years, stop the CDK and continue AI with close followup.

  • Jun 12, 2024

    Pending Moderator approval.

Further Reading